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Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage 
due to loss of response. There are scant data regarding the efficacy of shortening the dosing 
interval to 6 weeks. 
Aim 
We sought to investigate the efficacy of a once every 6 weeks' strategy compared with dose-
doubling. 
Methods 
This work was a multicentre retrospective study of infliximab-treated CD patients who 
required dose escalation. The clinical outcome of patients treated by intensification to 5 
mg/kg/6 weeks (6-week group) was compared with the outcome of patients whose infliximab 
was double-dosed (10 mg/kg/8 weeks or 5 mg/kg/4 weeks). 
Results 
Ninety-four patients (mean age: 29.8 years) were included in the study, 55 (59%) in the 6-
week group and 39 (41%) in the double-dose group. Demographics and disease characteristics 
were similar between the two groups, although patients with re-emerging symptoms 5-7 
weeks postinfusion were more likely to receive 5 mg/kg/6 weeks dosing (OR: 3.4, 95% CI: 
1.4-8.8, P < 0.01). Early response to dose-intensification occurred in 69% of patients in the 6-
week group and 67% in the double-dose group (P = N.S.). Regained response was maintained 
for 12 months in 40% compared with 29% of the patients respectively (P - N.S.). 
Conclusion 
In CD patients who lost response to standard infliximab dose, especially when symptoms re-
emerge 5-7 weeks postinfusion, shortening the dosing interval to 6 weeks appears to be at 
least as effective as doubling the dose to 10 mg/kg or halving the infusion intervals to once in 
4 weeks. 
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INTRODUCTION 
Crohn's disease (CD) is a disabling chronic inflammatory bowel disease. The anti-tumour 
necrosis factor alpha (TNF-α) infliximab is a monoclonal mouse-human chi-meric 
immunoglobulin that was introduced in the late 1990s. It has since been demonstrated to be an 
effective treatment for both luminal and fistulizing disease.1,2 Scheduled therapy with 
infliximab is associated with an increased likelihood of maintaining remission, reduced 
likelihood of development of antibodies to infliximab (ATI), reduced number of 
hospitalisations and cortico-steroid requirements.3,4 
Currently accepted regimen for scheduled administration of infliximab includes loading dose 
of 5 mg/kg at week 0, 2 and 6, followed by repeated infusions of 5 mg/kg every 8 weeks. 
However, 30-84% of the patents experience loss of response (LOR) to infliximab along the 
course of the treatment (1.4-7). It is advocated to try and induce regained response in these 
patients by either shortening the interval between the infusions or increasing the dose. The 
customary strategy and the only one reported in the framework of a controlled trial is 
doubling the dosage to 10 mg/kg every 8 weeks,1 although shortening the dosing interval to 4 
weeks is also common.5-8 In the ACCENT 1 trial, this double-dosing policy has lead to 
regained response in 80-90% of patients.1 However, rather than double-dosing, many 
physicians reduce the dosing interval to 6 weeks in those patients who experience a shortened 
duration of response.9 Although this approach may be less costly and could be more 
convenient for the patients, requiring clinic visit every 6 weeks instead of every 4 weeks, 
there are sparse data to support this clinical practice or its efficacy. 
Therefore, the aim of this retrospective multicentre study was to examine the efficacy of 
shortening the dosing interval of infliximab to every 6 weeks as compared with the 
conventional double-dose approach of halving the interval to every 4 weeks or escalating the 
dose to 10 mg/kg. 
METHODS 
Study design and population 
This work was an observational retrospective study of infliximab-treated CD patients in the 
years 2000-2009 at the gastroenterology departments of the participating tertiary medical 
centres. The study population comprised patients who have lost response to maintenance 
infliximab infusions of 5 mg/kg every 8 weeks as per their treating physician's judgment. The 
patients were divided to those whose therapeutic regimen was intensified to 5 mg/kg every 6 
weeks (group I) vs. those who received either 10 mg/kg every 8 weeks or 5 mg/kg every 4 
weeks (group II). Patient files were reviewed by an investigator in the participating institution, 
and clinical and laboratory parameters were recorded. The clinical outcome of regained 
response at 4-8 weeks after the first intensified dose infusion (immediate response) and after 1 
year (sustained response) was compared for patients in group I vs. group II. 
The study was approved by the institutional ethics committee of the Sheba Medical Center 
and also approved or exempted by the local ethics committees of the participating centres. 
Definitions 
Maintenance dosing was defined as at least one 8-week-interval infusion of infliximab 
following the induction course and prior to any dose escalation. Immediate response to 
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intensification was defined as improvement of the symptoms at the first clinic visit after dose 
intensification of infliximab as per the treating physician judgment, coupled with a decision to 
continue the intensified dose regimen without alterations. Long-term sustained response was 
defined as improvement of the symptoms on the intensified therapeutic regimen lasting at 
least 1 year without any further alterations of the therapeutic regimen. Failure of the 
intensified therapeutic regimen was defined by absence of improvement of the symptoms of 
disease and by a decision of the treating physician to increase the dose or shorten the dose 
interval of infliximab further, add immunomodulator or corticosteroids therapy, switch to 
another anti-TNF medication (Adalimumab/Certolizumab) or refer for CD-related surgery. 
Statistical analyses 
Continuous variables were analysed by two-tailed Student's t-test or Mann-Whitney U-test, as 
appropriate, and categorical variables were analysed by Fisher Exact test. On the basis of data 
from ACCENT l,1 we assumed 80% response for double dose and hypothesised a lessened 
response of 50% to the smaller dosing escalation of 5 mg/kg/6 weeks. To detect this 
difference with a power of 80% and with α-level of 5%, we computed that 72 patients (36 
patients in each arm) would be required. All statistics were performed using MedCalc 




Ninety-four patients were included in the study. Group I included 55 patients who were 
administered infliximab 5  mg/kg every 6 weeks. Group II included 39 patients whose dosing 
was intensified to either 10 mg/kg every 8 weeks (24 patients) or 5 mg/kg every 4 weeks (15 
patients). The demographic and disease characteristics of the study cohort, stratified into the 
two groups are depicted in Table 1. Five patients were formerly treated by episodic 
infliximab, but the treatment was stopped prior to resumption by a complete loading and 
maintenance scheduled therapy. The clinical data analysed for these patients refer only to 
their scheduled treatment phase. In three patients in group I and two patients in group II, the 
therapeutic regimen was successfully down escalated following sustained response to the 
escalation after a median duration of intensified treatment of 6  ± 1.7 (range: 3-9) months. The 
clinical data for these patients were analysed as per escalated regimen of infliximab. Eighteen 
of 94 patients achieved immediate response with an escalated regimen of infliximab (10 from 
group I and eight from group II), but have had a duration of follow-up of <l year. Thus, they 
were included in the outcome data analysis regarding the immediate response only. 
Immediate clinical response 
Overall, 64 of 94 (68%) study patients had short-term clinical response to intensified 
therapeutic regimen (Figure 1). Thirty-eight of 55 patients (69%) in group I experienced 
immediate short-term clinical response to shortening the therapeutic interval compared with 
26/39 (67%) in the double-dose group II (P > 0.9). The median time to first visit after 
escalation when response was determined was 6 ± 2.2 (2-8) weeks. 
Elevated CRP level before the escalation was present in 69 of 79 patients with available 
measurement, but was not predictive of greater response to escalation (data not shown). 
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Sequential CRP level both before and after treatment intensification was available in 64 of the 
94 patients, and was elevated above the upper normal limit in 56 of these 64 patients before 
escalation. Intensification of the therapeutic regimen resulted in normalisation of the CRP in 
26 of these 56 (46%) patients. Immediate response to escalation occurred among 22/26 
patients with CRP normalisation compared with 17 of 30 with persistent elevation of CRP 
(OR: 4.2, 95% CI: 1.2-15.2, P = 0.03). 
Sustained clinical response 
Twenty-seven (36%) of the 76 patients who completed follow-up period of at least 1 year had 
a sustained clinical response at 12 months after infliximab intensification (median follow-up: 
-1.9 years). The course and subsequent therapies employed for the individual study patients 
are shown in Figure 2. In group I, 18/45 (40%) patients with complete follow-up had 
sustained their response at 1 year compared with nine of 31 (29%) of patients in group II (P = 
0.65). The median duration of sustained response was 16 ± 10.7 (range: 12-52,) months in 
group I and 17 ± 16.4 (range: 12-60) months in group II (P = 0.99). A Kaplan-Meier curve 
depicting the cumulative incidence over time for LOR to the intensified regimen for the two 
groups is shown in Figure 3. No demographic or clinical factor was found to be predictive for 
sustained response to escalation regimen of infliximab (Table 2). 
We also divided patients to those with early post-infusion LOR (re-emerging symptoms <4 
weeks postinfusion, n = 27) vs. those with late postinfusion LOR (symptoms occurring 5-7 
weeks postinfusion, n = 67). This analysis showed that early postinfusion LOR patients were 
more likely to be double-dosed than to receive 5 mg/kg/6 weeks (17/39 vs. 10/55, OR: 3.4, 
95% CI: 1.4-8.8, P < 0.01), whereas patients with late postinfusion LOR mostly received 
shortened 6 weeks' interval infusions (Table 1). In terms of efficacy, however, both strategies 
yielded comparable rates of sustained response among the 76 patients with complete follow-
up: 15/36 patients with late postinfusion LOR treated by 5 mg/kg/6 weeks were still 
responding at 12 months compared with six of 18 patients with late LOR treated by double-
dosed regimen (P = N.S.). Sustained response was also comparable for patients with early <4 
weeks postinfusion LOR treated by either strategy, but the numbers of patients were smaller 
(3/13 vs. 3/9, for 5 mg/kg/6 weeks vs. double dose respectively). 
Finally, we analysed the results for sustained clinical response at 1 year or at the end of 
follow-up by incorporating the 18 patients with <l year of follow-up (mean follow-up duration 
of 0.6 years). There was no difference in the sustained response rate between group I and 
group II in this analysis as well (28/55 vs. 17/39 respectively, P = 0.56). 
Second escalation of infliximab dosage 
Forty-nine patients of the total cohort did not achieve sustained clinical response after the first 
escalation of infliximab dosage. In 28/49 (57%) of these failing patients, a further dose 
escalation of infliximab was attempted. Eleven (39%) of the 28 patients responded to a second 
escalated infliximab dosage (mean follow-up time: -1.1 years). The clinical course of these 
patients and their breakdown to patients receiving second escalation after previous 6 week 
regimen vs. previous double dose is described in Figure 1 and Table 3. Considered together, 
first and second escalations resulted in 38/76 (50%) of patients being in sustained clinical 
response at 12 months after initial LOR 
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Table 1  Demographic and clinical characteristics of the included patients 
 Entire cohort (n = 94) Group I (n = 55) Group II (n = 39)  
 n % n % n  % P 
Age at diagnosis (years) 
<16 17 18 7 13 10  26 0.19 
16-40 68 72 41 75 27  69 0.87 
>40 9 10 7 13 2  5 0.31 
Age at initiation of 
infliximab therapy (years) 
29.8 ± 10.3 31.9 ± 10.6 27 ± 9.3 0.5 
Duration of disease before 
initiation of IFX (years) 
10.4 ± 6.8 10.7 ± 6.7 9.14 ± 6.3 0.79 
Gender 
Male 44 47 25 45 19  49 0.85 
Female 50 53 30 55 20  52 1 
Location 
Upper 3 3 1 2 2  5 0.57 
Small bowel 19 20 12 22 13  18 0.37 
Colon 21 22 8 15 7  33 0.78 
lleocolonic 54 58 35 64 19  49 0.48 
Disease phenotype 
Fistulizing 20 21 10 18 10  26 0.52 
Stricturing 36 38 24 44 12  31 0.86 
Perianal 38 40 20 36 15  39 0.49 
Concurrent medications 
Thiopurines 50 53 27 49 23  59 0.43 
Methotrexate 6 6 6 11 0  0 0.76 
Budesonide 6 6 3 6 3  8 0.73 
Systemic CS 1 1 0 0 1  3 1 
5-ASA 15 16 4 7 11  28 0.12 
Postinfusion time to LOR (time of re-emerging symptoms) response 
Early (<4 weeks) 27 29 10 18 17  44 0.01 
Late (>4 weeks) 67 71 45 82 22  56 0.01 
Number of maintenance IFX 
infusions until LOR, median 
(range) 




79 84 44 80 35  90  
Elevated CRP before 
escalation 
69 87 38 86 31  89 0.59 
Group I patients were switched to infliximab 5 mg/kg/6 weeks. Group II patients were intensified to infliximab 10 mg/kg/ 8 weeks or 5 
mg/kg/4 weeks (double dose). 






Published in: Alimentary Pharmacology & Therapeutics (2010), pp. 1-9 
Status: Postprint (Author’s version) 
DISCUSSION 
The present study evaluated the efficacy of shortening the dosing interval of infliximab to 
once in every 6 weeks in patients who lost response to standard maintenance regimen, in 
comparison to doubling the dose or halving the dosing interval to once in every 4 weeks. 
There are limited data pertaining to the rates of LOR and regain of response to intensified 
dose. In particular, data regarding the optimal dose intensification protocol in such patients 
are lacking. 
In the ACCENT 1 study, 29% of the patients receiving scheduled infusions of infliximab 
experienced worsening of symptoms requiring dose increase.1 Of these patients, 80-90% 
responded to the intensified dose, but the rate of 1 year sustained response to the escalated 
regimen was not reported due to the design of the study. Requeiro et al7 found that in a cohort 
of patients who received at least eight doses of infliximab (both scheduled and episodic), 31% 
of the patients required dose intensification after 12 months and 54% after 30 months. 
Overall, 76% of these patients remained under infliximab treatment at the conclusion of 
follow-up, but data regarding possible additional interventions in these patients and the 1-year 
response rate were not reported. In a cohort of 614 patients receiving either episodic or 
maintenance treatment with infliximab, 50% required some change of treatment regimen 
including switch from episodic to scheduled treatment, shortening of dosage interval or dose 
escalation.5 However, data pertaining specifically to each of these policies, and the response at 
12 months were not provided. Thus, to the best of our knowledge, this study is the first to 
assess specifically the sustained response to escalation at the clinically meaningful 12 months' 
time point. 
 
Figure 1  Short- and long-term response to escalation regimen of infliximab. Group I patients 
were switched to infliximab 5 mg/kg/6 weeks. Group II patients were intensified to infliximab 
10 mg/kg/8 weeks or 5 mg/kg/4 weeks (double dose). 
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Figure 2  The clinical course of the patients treated with escalated dose of infliximab (IFX). Group I patients were switched to infliximab 5 
mg/kg/6 weeks. Group II patients were intensified to infliximab 10 mg/kg/8 weeks or 5 mg/kg/4 weeks (double dose). Additional medication - 
systemic corticosteroids or methotrexate. ADA, Adalimumab. 
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Figure 3  Cumulative probability of loss of response over time for the two treatment groups. 
Group I patients were switched to infliximab 5 mg/kg/6 weeks. Group II patients were 
intensified to infliximab 10 mg/kg/8 weeks or 5 mg/kg/4 weeks (double dose). 
 
 
There are few systematic data regarding the shortening of the dosing interval to once every 6 
weeks rather than double dosing or halving the interval. A study by Seow et al10 in patients 
receiving maintenance infliximab therapy for ulcerative colitis demonstrated that in patients 
who had lost response to 5 mg/kg of infliximab every 8 weeks, shortening of the dosing 
interval to 6-7 weeks resulted in regained remission in 44% of the patients, whereas doubling 
the dose resulted in regained remission in 25% of the patients, but the duration of the regained 
remission was not reported. Magro et al9 found that shortening the dosing interval to 6 weeks 
was an efficient strategy for managing LOR in CD patients receiving maintenance treatment 
with infliximab. However, this was a small-scale retrospective study that included only 15 
patients. 
Infliximab has linear pharmacokinetics with elimination half-life of 12 days and no plasma 
level accumulation with multiple infusions,11 so a 6-week-interval  approach appears to be 
acceptable and safe from the pharmacological point of view. St Clair et al12 performed a 
pharmacokinetic modelling for escalation of infliximab based on the cohort of rheumatoid 
arthritis patients. This model concluded that shortening the dose interval to every 6 weeks 
would increase the median serum trough level 3.5-fold compared with 2.2-fold increase in 
trough level after a 50% increase in infliximab dose given every 8 weeks. However, the 
validity of these calculations was not confirmed by actual infliximab concentration 
measurements, and efficacy of shortened 6-week dosing intervals was not clinically evaluated 
in the study. 
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Table 2  Predictors of sustained (12 months) response to infliximab escalation 
 Sustained response (n = 27) Failure to achieve 
response (n = 49) 
 
 n  % n  % P-value 
Age at diagnosis (years)  23.5 ± 9.4   26 ± 10.4  0.19 
Age at initiation of infliximab 
therapy (years) 
 29.8 ± 10.2   31.1 ± 10.6  0.36 
Duration of disease before 
initiation of IFX (years) 
 7.47 ± 6.7   5.26 ± 5.5  0.13 
Female 11  59 23  47 0.67 
Male 16  41 26  53 0.67 
Location 
Upper 0  0 2  4 0.54 
lleocolonic 14  52 24  49 1 
Small bowel 5  19 20  41 0.21 
Colonic 5  19 5  10 0.48 
Disease phenotype 
Fistulizing 8  30 10  20 0.59 
Stricturing 8  30 17  35 0.81 
Perianal 9  33 16  33 1 
Concomitant medications 
Thiopurines 14  52 26  53 1 
Methotrexate 2  7 3  6 1 
Budesonide 2  7 4  8 1 
5-ASA 7  26 5  10 0.2 
Median number of maintenance 
IFX infusions until LOR (range) 
9 ± 7.8 (0-25) 6 ± 8.9 (0-36) 0.49 
Postinfusion time to LOR (time of re-emerging symptoms) 
Early (<4 weeks) 6  27 16  73 0.14 
Late (>4 weeks) 21  39 33  61 0.14 
CRP above normal before first 
escalation* 
19  82 37  80 0.8 
IFX, infliximab; CS, corticosteroids; CRP, C-reactive protein; LOR, loss of response.  
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Table 3  Number of patients receiving and responding to second escalation regimens of 
infliximab dose 
  Second 
escalation 
5 mg/kg/ 4 
weeks 
10 mg/ kg/6 
weeks 
10 mg/ kg/4 
weeks 
15 mg/ kg/8 
weeks 
5 mg/kg/ 5 
weeks 
Group Failure of 
first 
escalation 
Total Resp Total Resp Total Resp Tota
l 
Resp Total Resp Total Resp 
Group I 27 21 8 12 7 8 1 - - - - 1 0 
Group II 22 7 3 - - 2 2 4 0 1 1 - - 
Total 49 28 11 12 7 10 3 4 0 1 1 1 0 
Total, total number of patients in the subgroup; Resp, number of patients that responded to the escalation. 
 
Arguably, shortening the dosing interval to 5 mg/kg every 6 weeks is appropriate for patients 
with shortened response to infliximab, whereas double dosing (or interval halving) should be 
reserved for patients with complete or early LOR to the last infusion.8 Although this rationale 
is clinically sound, and has underlain physicians' therapeutic choices for a majority of patients 
in our study as well, the clinical outcomes of these differing policies have not been previously 
investigated. Thus, we believe this study is important for being the first to compare between 
these two management approaches. The results suggest that escalation of the therapeutic 
regimen to once every 6 weeks appears to be at least as effective as doubling the dose or 
halving the interval, especially for patients with late postinfusion LOR (re-emerging 
symptoms 5-7 weeks postinfusion). This preliminary evidence supporting the validity of the 5 
mg/kg/6 weeks intensification policy is also important given the significant costs incurred by 
these escalation regimens. In fact, based on published U.S. costs of $662/100 mg infliximab 
and $193 per infusion,13 keeping a 60-kg patient on 5 mg/kg/6w for 12 months would cost 
US$19 611 compared with US$24 990-26 148 for the double-dose strategies, amounting to a 
$5379-6537 savings in cost per patient per annum. 
The overall rate of primary nonresponse to the first escalation was 32%, and many of the 
responding patients subsequently lost response to the escalated regimen within <l year of 
treatment. Nevertheless, an important observation of the study is that nearly 40% of patients 
without a sustained response to the first escalation (either primary or secondary 
nonresponders) may still regain response to a second elevation of infliximab dose or further 
shortening of the dosing interval. Taken together, dose-intensification policy (with either one 
or two dose increases) results in an approximately 50% rate of sustained response at 12 
months after LOR to standard maintenance therapy. 
A major limitation of this retrospective study is the absence of response criteria based on 
clinical scoring systems. However, from the practical point of view, the patient's report and 
the clinician's decision regarding continuation or change in the therapeutic regimen probably 
reflects the real-life assessment of the severity of the disease and the clinical decision making. 
Although the involvement of several centres could contribute to heterogeneity of the 
clinician's assessment of the patient's response, it also lends further support to the wider 
clinical relevance of the observations as they are derived from several tertiary centres rather 
than any single centre with a particular policy. 
As alluded to above, another possible limitation stems from a basic difference between the 
two groups in the sense that physicians have opted to intensify the dose to once every 6 weeks 
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in patients reporting shortened response of 5-7 weeks to the last infusion, whereas they tended 
to double dose in patients experiencing little effect of the infusion whatsoever. Nonetheless, 
upon sub-analysing the efficacy of escalation strategies for patients with late postinfusion 
LOR, 5 mg/kg/6w was at least as effective as double dosing. The strategies were also 
comparable when applied for patients with early postinfusion LOR, albeit the numbers of 
patients in this subanalysis were small. Thus, the present results are clinically pertinent for 
substantiating that the two approaches are comparable, especially for patients with late 
postinfusion LOR (re-emerging symptoms 5-7 weeks postinfusion). Nonetheless, a cautionary 
note should be placed, as this study was not designed as a non-inferiority study, and can not 
definitively exclude the presence of a difference -albeit small - in the efficacy of the two 
policies. 
Finally, infliximab drug level and presence or absence of ATI were previously shown to 
correlate with LOR14-16 and to be helpful in directing therapy,17 but were mostly unavailable 
for the present study patients. Colonoscopy findings before/after dose-adjustment were also 
unavailable. Although these shortcomings do not affect the validity of the observations, it 
would be important in the future to analyse the rates of regained response by different 
escalation protocols in association with drug level, ATI status and endoscopic mucosal 
healing. 
In conclusion, in patients with CD and LOR to infliximab, escalation of the infliximab dosing 
to once every 6 weeks appears to be at least as effective as doubling the dose or halving the 
dosing interval to every 4 weeks, and results in sustained response in 40% of patients. 
However, these preliminary data should be corroborated by a larger scale and preferably a 
prospective controlled study comparing the regained response rate to 5 mg/kg/6w vs. the 
double-dose strategy in patients with LOR to infliximab, stratified by early or late 
postinfusion re-emergence of symptoms. 
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